Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
Michael E. Bozik, Pittsburgh, PA (US); Gregory Hebrank, Greensburg, PA (US); Wildon Farwell, Wayland, MA (US); Thomas Petzinger, Jr., Pittsburgh, PA (US); and Steven Dworetzky, Jefferson Hills, PA (US)
Assigned to Areteia Therapeutics, Inc., Chapel Hill, NC (US)
Filed by ARETEIA THERAPEUTICS, INC., Chapel Hill, NC (US)
Filed on Mar. 6, 2023, as Appl. No. 18/118,012.
Application 18/118,012 is a continuation of application No. 16/950,973, filed on Nov. 18, 2020, granted, now 11,612,589.
Application 16/950,973 is a continuation of application No. 15/923,650, filed on Mar. 16, 2018, granted, now 11,026,928, issued on Jun. 8, 2021.
Application 15/923,650 is a continuation of application No. 14/904,058, granted, now 10,828,284, issued on Nov. 10, 2020, previously published as PCT/US2014/046380, filed on Jul. 11, 2014.
Application 14/904,058 is a continuation in part of application No. PCT/US2013/054804, filed on Aug. 13, 2013.
Application 14/904,058 is a continuation in part of application No. 13/966,229, filed on Aug. 13, 2013, granted, now 9,468,630, issued on Oct. 18, 2016.
Claims priority of provisional application 61/859,158, filed on Jul. 26, 2013.
Claims priority of provisional application 61/845,944, filed on Jul. 12, 2013.
Claims priority of provisional application 61/865,118, filed on Aug. 12, 2013.
Prior Publication US 2023/0277509 A1, Sep. 7, 2023
1. A method of treating a condition characterized by increased numbers of eosinophils in a subject comprising:
administering to a subject in need thereof a therapeutically effective amount of R(+) pramipexole, or a pharmaceutically acceptable salt thereof, wherein the condition is a gastrointestinal disease.
